{"id":"ck-2017357","safety":{"commonSideEffects":[{"rate":"null","effect":"dyspnea"},{"rate":"null","effect":"fatigue"}]},"_chembl":{"chemblId":"CHEMBL1234574","moleculeType":"Small molecule","molecularWeight":"284.38"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"CK-2017357 works by inhibiting the myosin ATPase activity of cardiac myosin, leading to increased cardiac contractility and improved heart function. This mechanism is thought to be beneficial for patients with heart failure.","oneSentence":"CK-2017357 is a cardiac myosin inhibitor that increases cardiac contractility.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:08:10.608Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertrophic cardiomyopathy"}]},"trialDetails":[{"nctId":"NCT02936635","phase":"PHASE3","title":"A Study for Patients Who Completed VITALITY-ALS (CY 4031)","status":"COMPLETED","sponsor":"Cytokinetics","startDate":"2016-10-17","conditions":"Amyotrophic Lateral Sclerosis (ALS)","enrollment":280},{"nctId":"NCT02496767","phase":"PHASE3","title":"Ventilatory Investigation of Tirasemtiv and Assessment of Longitudinal Indices After Treatment for a Year","status":"COMPLETED","sponsor":"Cytokinetics","startDate":"2015-09-03","conditions":"Amyotrophic Lateral Sclerosis","enrollment":744},{"nctId":"NCT01709149","phase":"PHASE2","title":"Study of Safety, Tolerability & Efficacy of CK-2017357 in Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Cytokinetics","startDate":"2012-10","conditions":"Amyotrophic Lateral Sclerosis","enrollment":711},{"nctId":"NCT01268280","phase":"PHASE2","title":"Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis","status":"TERMINATED","sponsor":"Cytokinetics","startDate":"2010-12","conditions":"Myasthenia Gravis","enrollment":32},{"nctId":"NCT01131013","phase":"PHASE2","title":"A Study of CK-2017357 in Patients With Peripheral Artery Disease and Symptomatic Claudication","status":"COMPLETED","sponsor":"Cytokinetics","startDate":"2010-05","conditions":"Intermittent Claudication, Peripheral Artery Disease","enrollment":61},{"nctId":"NCT01089010","phase":"PHASE2","title":"A Study of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Cytokinetics","startDate":"2010-03","conditions":"Amyotrophic Lateral Sclerosis","enrollment":67},{"nctId":"NCT01378676","phase":"PHASE2","title":"A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Cytokinetics","startDate":"2011-06","conditions":"Amyotrophic Lateral Sclerosis","enrollment":49},{"nctId":"NCT01486849","phase":"PHASE2","title":"Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)","status":"COMPLETED","sponsor":"Cytokinetics","startDate":"2011-11","conditions":"Amyotrophic Lateral Sclerosis","enrollment":27}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["tirasemtiv"],"phase":"phase_2","status":"active","brandName":"CK-2017357","genericName":"CK-2017357","companyName":"Cytokinetics","companyId":"cytokinetics","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CK-2017357 is a cardiac myosin inhibitor that increases cardiac contractility. Used for Hypertrophic cardiomyopathy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}